ARTICLE SUMMARY:
Immunotherapy has become a cornerstone of cancer treatment, presenting the opportunity of a lifetime for the biopharma industry, but until now, devices have played a minimal role in its success. Recent scientific advances have led to a belief, however, that devices can boost the efficacy of immuno-oncology drugs by priming the immune response and/or enhancing the abscopal effect in metastatic disease.
In May 2016, the Janssen Biotech subsidiary of Johnson & Johnson, and Weill Cornell Medicine agreed to collaborate on preclinical studies of how radiation oncology combined with immuno-oncology drugs could enhance treatment for various types of cancers.
